The University of Cambridge and Elan Corporation plc today announced the launch of The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England.
28 November, 2011
Celgene, one of the world’s largest developers of biopharmaceuticals has demonstrated its commitment to UK expansion with the opening of its new London headquarters, accommodating its growing numbers of UK staff and the Celgene global regulatory and drug safety teams.
23 November, 2011
Biomarkers. There was a time in the not-so-distant past when simply identifying a biomarker was considered a drug discovery success. Like the low hanging fruit initially exposed by the genomic revolution, that once common view has long since disappeared. Today, the line between the bench and the clinic is becoming increasingly blurred. Translational science has become a core element of the drug discovery paradigm, and with it has come an increasing need for an integrated, multidisciplinary approach to biomarker development.
23 November, 2011
As consumers and health systems move toward greater reliance on self-care, regulatory and clinical decision making should be improved through new tools to assess the unique benefits and challenges of self-care nonprescription [‘over-the-counter’, (OTC)] products, according to a new White Paper published in the peer-reviewed journal Clinical Pharmacology & Therapeutics.
16 November, 2011
Pantarhei Bioscience, a specialty pharmaceutical company focusing on the development of innovative, proprietary treatments in the fields of women’s health and endocrine cancer, announces the publication in the Journal of the Federation of American Societies for Experimental Biology (FASEB J October 5, 2011) of the results of an innovative treatment strategy for ovarian cancer, which has now been selected to appear in the Faculty of 1000 (F1000) emphasizing its significance.
15 November, 2011
The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
14 November, 2011
The company behind a pioneering stem cell bandage, believed to be the world’s first adult and autologous (patient’s own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK’s most successful entrepreneurs.
14 November, 2011
A new educational campaign is being launched in the UK to educate people with type 2 diabetes on ‘hypoglycaemia’ and how it can be prevented and managed. The ‘Are You Running on Empty?’ campaign is collaboration between Diabetes Nursing Group, TREND, The Automobile Association (AA) and MSD Diabetes.
08 November, 2011
Almac’s Diagnostics business unit today announced the publication of its stage II colon cancer recurrence signature (diagnostic test) in the Journal of Clinical Oncology.
08 November, 2011
Domainex Ltd, the UK-based drug discovery company focused on speed and innovation, has been awarded a £250,000 grant by the Technology Strategy Board (TSB), the UK’s national innovation agency, to help support the development of a new drug for the treatment of several common cancers.
01 November, 2011